Biomarkers for Early Cancer Detection: Promising Approaches in Cellular Oncology

Persian Brat^*
*Correspondence: Persian Brat, Department of Oncology, University of Dudley, Dudley, UK, Email:

Introduction

Early cancer detection is crucial for improving patient outcomes, as many cancers are more treatable in their early stages. Biomarkers are substances that can be measured in the body and indicate the presence of cancer or the risk of developing it. Various types of biomarkers are used in cancer research and diagnostics. Cancer pain is a complex phenomenon involving various mechanisms. It can result from the direct pressure or invasion of tumors on nerves or tissues, the release of inflammatory mediators, and neuropathic changes in the nervous system. While the study did not collect information on cancer type, disease history, or treatment within the past year, it provides valuable insights into the safety and effectiveness of COVID-19 vaccines in cancer patients.

Description

These are substances produced by cancer cells or other cells in response to the presence of cancer. Common tumor markers include PSA (Prostate- Specific Antigen) for prostate cancer, CA-125 for ovarian cancer, and CEA (Carcinoembryonic Antigen) for colorectal cancer. However, tumor markers are not always specific to cancer and may be elevated in non-cancerous conditions. Mutations in certain genes can increase the risk of cancer. For example, BRCA1 and BRCA2 mutations are associated with breast and ovarian cancer. Genetic testing can identify these mutations and assess the risk of cancer. CTCs are cancer cells that have detached from the primary tumor and entered the bloodstream. Detection and analysis of CTCs in a blood sample can provide valuable information about cancer progression and help predict treatment outcomes. MicroRNAs are small RNA molecules that can regulate gene expression. Specific microRNAs are associated with various cancer types, and their levels in blood or tissue samples can indicate the presence of cancer.

Proteomics involves the study of proteins in the body. Changes in the expression or structure of certain proteins can be indicative of cancer. Techniques like mass spectrometry can be used to analyze protein profiles. Epigenetic changes, such as DNA methylation and histone modification, can play a role in cancer development. These changes can be detected in various bodily fluids and tissues and used as markers for cancer risk and early detection. Liquid biopsies involve analysing components of blood or other bodily fluids for genetic mutations, CTCs, cell-free DNA, and other markers of cancer. Liquid biopsies are non-invasive and can provide real-time information about cancer status. Imaging techniques like MRI, CT, and PET scans can also be used to detect early signs of cancer by visualizing abnormalities in tissues or organs.

Chronic inflammation can increase the risk of cancer, and elevated levels of certain inflammatory markers, like C-reactive protein, can be associated with cancer development. Cancer is caused by mutations in genes that control cell growth and division, and DNA damage plays a crucial role in the development of these mutations. Mutations can accumulate in a cell's DNA due to exposure to various environmental factors, including tobacco smoke, radiation, and certain chemicals. However, mutations can also arise spontaneously during DNA replication, even in the absence of external factors. When the proteins that normally repair DNA damage are not working properly due to gene mutations, these mutations can accumulate and spread throughout the cell and its daughter cells, leading to additional abnormalities. Some of these mutated cells die, while others acquire a selective advantage that allows them to multiply much more rapidly than normal cells. However, more recent studies have shed some light on this issue. Changes in metabolic pathways can be indicative of cancer. Metabolomic profiling can identify altered metabolites that serve as cancer biomarkers [1-5].

Conclusion

Overall, It's important to note that no single biomarker is definitive for cancer diagnosis, and a combination of approaches is often used. Additionally, ongoing research is continually uncovering new potential biomarkers for early cancer detection, and advancements in technology are making detection methods more sensitive and accurate. Regular screening and consultation with a healthcare professional are crucial for early detection and effective cancer management.

Acknowledgement

We thank the anonymous reviewers for their constructive criticisms of the manuscript. The support from ROMA (Research Optimization and recovery in the Manufacturing industry), of the Research Council of Norway is highly appreciated by the authors.

Conflict of Interest

The Author declares there is no conflict of interest associated with this manuscript.

References

1. Epstein, Joel B., Juliette Thariat, Rene‐Jean Bensadoun and Andrei Barasch, et al. "Oral complications of cancer and cancer therapy: From cancer treatment to survivorship." CA: A Cancer Journal for Clinicians 62 (2012): 400-422.

Google Scholar, Crossref

2. Salazar, Carolina, Rahul Nagadia, Pratibala Pandit and Justin Cooper-White, et al. "A novel saliva-based microRNA biomarker panel to detect head and neck cancers." Cell Oncol 37 (2014): 331-338.

Google Scholar, Crossref, Indexed at

3. Pucci, Carlotta, Chiara Martinelli and Gianni Ciofani. "Innovative approaches for cancer treatment: Current perspectives and new challenges." Ecancermedicalscience 13 (2019).

Google Scholar, Crossref, Indexed at

4. Warren, Joan L., K. Robin Yabroff, Angela Meekins and Marie Topor, et al. "Evaluation of trends in the cost of initial cancer treatment." JNCI 100 (2008): 888-897.

Google Scholar, Crossref, Indexed at

5. Martin, D. and J. S. Gutkind. "Human tumor-associated viruses and new insights into the molecular mechanisms of cancer." Oncogene 27 (2008): S31-S42.

Google Scholar, Crossref, Indexed at